Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRAJ37 (T cell receptor alpha joining 37) is a joining (J) gene segment of the human T cell receptor alpha chain locus. It encodes a short region (22 amino acids) that is somatically recombined with variable (V) gene segments during T cell development, forming part of the antigen-binding region of the TCR alpha chain. The function of TRAJ37, like other TRAJ segments, is to contribute to the diversity of TCRs required for antigen recognition in the adaptive immune system. TRAJ37 itself is not a stand-alone molecule or receptor, nor is it a therapeutic target. Instead, it serves a genetic role in generating immune receptor diversity through VJ recombination in T lymphocytes[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 37 (TRAJ37).